The FDA's Drugs@FDA database lists a supplement dated 2 October 2026 to an abbreviated new drug application for synthetic exenatide, held by a generic manufacturer. The entry gives only the application number, the company and the drug name. It does not say what the supplement changed.
A supplement to a generic application can cover manufacturing, labelling or other changes, and most are administrative. Nothing in this record is a new indication or a safety communication. If you prescribe or dispense a synthetic exenatide product, the current prescribing information is the place to check for any change.
Indian availability of this specific product and CDSCO's position are not stated in the record and are unknown here.
- The entry names the application and company but not the change.
- It is a supplement to a generic application, not a new approval or safety alert.
- Check the current prescribing information for the product you use.
- Do not change prescribing on the strength of this entry.
Why it matters
Most supplements to generic applications are administrative and do not change what a prescriber should do.
Don't overread it
A supplement is not a new indication, and the record does not describe the change.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free